Overview
Refralon® tablets in two different doses (1 or 2 tablets per day) will be evaluated vs. placebo in patients with persistent atrial fibrillation/flutter after synus rhythm restoration in order to prevent recurrence of arrhythmia. Efficacy and safety of Refralon® tablets will be studied, its optimal dose will be selected and its pharmacokinetics will be evaluated in 14 days, 1, 3 and 6 months.
Eligibility
Inclusion Criteria:
- Persistent form of AF/AFL lasting 7 days - 1 year (including patients who have previously undergone ineffective catheter or surgical ablation of AF or AFL and patients with a pacemaker or implanted cardioverter-defibrillator (ICD));
- Basic rhythm - AF and/or AFL according to the results of 12-lead ECG at randomization (Visit 2);
- Left ventricular ejection fraction (LVEF) >40% according to the Simpson method;
Exclusion Criteria:
- Intake of class IA, IC and class III antiarrhythmic drugs less than 7 days (for amiodarone less than 60 days) before the study drug intake;
- History of myocardial infarction or other structural heart disease;
- QT prolongation over 500 ms.